| INTRODUCTION
Translational research and drug discovery for rare genetic diseases have grown at a rapid pace. A PubMed search conducted in April 2016, using "rare diseases" and "orphan diseases" as keywords, showed that publications related to rare diseases or orphan diseases have significantly increased over the past two decades (Figure 1a ). Advances in rare disease diagnostics and pharmacogenomics have allowed better characterizations of rare diseases, especially those that are monogenic.
Approximately 7,000 rare diseases have been identified and many have a known etiology (https://rarediseases.info.nih.gov/). Although a rare disease in the United States (US) is defined as one that affects fewer than 200,000 individuals in the US, a staggering 20-30 million Americans currently live with a rare disease (Schieppati, Henter, Daina, & Aperia, 2008) , representing a significant collective burden.
In 1983, the Orphan Drug Act (ODA) (Sanders, 1983) was passed in the US to promote the development of treatments for rare diseases. In the decade before the ODA, only ten drugs for rare diseases had received the US Food and Drug Administration (FDA) approval, compared to more than 300 orphan drug approvals in the subsequent 25 years (Haffner, 2006) . Based on the nature of molecular and developmental processes, a drug can be approved either as a new molecular entity (NME) or through a biologics license application (BLA). A NME is a drug that has not been marketed in the US in any form. BLA refers to the submission process that contains specific information on the manufacturing product. The number of NMEs and BLAs approved by the Center for Drug Evaluation and Research (CDER), a division of the FDA, increased from 5 in 2006 to 21 in 2015 for rare diseases (Figure 1b) . Orphan drugs, a term describing medications used to treat rare diseases, may offer several potential advantages, including shorter development timelines, lower cost of research and development, and less generic competition (Melnikova, 2012) .
In recent years, more than 35% of FDA-approved new drugs have been for the treatment of rare diseases. In turn, commercial activity in this sector has gained momentum. In 2015, two pharmaceutical companies bought rare disease assets in lucrative deals (Micklus & Muntner, 2016) . Although the overall rare disease markets are notable, cost of treatment per patient may be high due to the limited number of patients suffering from each individual rare disease.
Several factors have hindered therapeutic development for rare diseases. For example, heterogeneity in disease pathophysiology can cause large variations in drug response. Progression of many rare diseases is poorly understood due to limited natural history studies.
Inadequate numbers of patients recruited for clinical trials lead to outcomes lacking statistical significance. Absence of biomarkers to measure disease also contributes to the ambiguity of clinical studies of rare diseases. The heterogeneity of rare diseases increases the challenges that are faced in developing effective treatments. For example, Niemann-Pick disease type C (NPC) has over 200 missense mutations in the NPC1 gene that all result in a similar disease phenotype (Runz, Dolle, Schlitter, & Zschocke, 2008) . Congenital ichthyosis, a scaly skin disease, has more than 30 known subtypes with overlapping clinical phenotypes associated with different gene mutations (Dunoyer, 2011) . The same drug will inevitably result in variable degrees of efficacy due to the different mutations that they carry, even though the patients are diagnosed as having the same disease. This also brings a unique opportunity for researchers and clinicians to move into the pharmacogenomics era.
The lack of natural history studies for most rare diseases renders patient ascertainment and recruitment more challenging than common diseases. For some ultra-rare diseases, there are fewer than 100 patients worldwide. Farber disease represents one such extreme example, with about 80 patients reported around the world.
| FUNDING FOR RARE DISEASE DRUG DEVELOPMENT
Although the issue of commercial return on investment has been partially addressed with legislation and with some for-profit companies having robust business models, lack of funding for rare disease drug development remains, especially for early preclinical research. There are several efforts to address this disparity. The National Organization for Rare Disorders (NORD) (http:// rarediseases.org/) has been successful in the past at lobbying the US Congress for improvements to the ODA (Brooks, Yang, & Austin, 2016) . NORD provides referrals to more than 2,000 different organizations representing specific rare diseases. The organization has also provided funds through small grant programs to help develop drugs/treatments for rare diseases, which can help the collection of pilot data in order to apply for larger financial support through the NIH or other mechanisms. The NIH has programs to fund rare disease research, and the NIH official policy is to not consider the number of patients affected for a given disease when considering whether to fund an application. This policy helps to balance the funding for rare disease research.
Another alternative for funding of rare disease research resides in patient advocacy groups and foundations, which focus on a particular rare disease and often bring the disease researchers together. In recent years, while the regular funding sources have become more competitive, the funding for rare diseases appears to have remained steady. The FDA Office of Orphan Products Development (OOPD) is a major funding source for clinical grants that helps bridge the gap between basic research, clinical development, and marketing approval FIGURE 1 (a) Publications for rare and orphan disease research indexed in MEDLINE from 1996 to 2015. The search was conducted in April 2016 in PubMed using "rare diseases" and "orphan diseases" as keywords. (b) Number of new molecular entities (NMEs) and Biologics License Applications (BLAs) approved by the Center for Drug Evaluation and Research (CDER) from 2006 to 2015. Data are from the FDA website (http://www.accessdata.fda.gov/scripts/cder/daf/). (Dunoyer, 2011) . These grants only cover portions of phases I, II, and III clinical trials and do not fund preclinical development. OOPD grants are especially useful for academic researchers. These academically derived early assets can in turn be licensed to pharmaceutical/biotech companies for further development or commercialization. To improve the drug development and clinical study of rare diseases, the FDA itself offers specific incentives and expedited programs, such as orphan drug designation and exclusivity, a pediatric rare disease priority review voucher, fast track, and priority review.
| SMALL MOLECULE DRUG DEVELOPMENT FOR RARE DISEASES
The drug development process for rare diseases is similar to that for common diseases, which requires significant resources and typically lasts 10-12 years. Drugs from small molecules represent approximately 80-90% of the marketed therapeutics and have a number of advantages, including well-defined structures, relatively easy manufacturing, oral administration, and mostly non-immunogenic profiles. In addition, many of them can cross the blood-brain barrier to reach the central nervous system. From 2000 to 2008, 22% of NMEs approved by the FDA were orphan drugs, the majority of which were small molecules (Sun, Sanderson, & Zheng, 2016) . 
| Target identification
With advancements in molecular biology and the recent success in the identification of potential druggable genomic targets in the human SUN ET AL. | 2309 genome (Aguero et al., 2008) , molecular target-based drug discovery has become the predominant approach (Eder, Sedrani, & Wiesmann, 2014) . Whole genome or exome sequencing offers valuable opportunities to identify the causes of rare diseases. A protein target such as an enzyme, a receptor, or an ion channel related to a disease pathophysiology is usually first identified. Approaches in target identification such as direct biochemical methods, genetic interaction methods, and computational inference methods have been recently reviewed (Schenone, Dancik, Wagner, & Clemons, 2013) .
| Assay development
Once a disease target is identified, a specific assay needs to be developed to determine the candidate's therapeutic activity. The Assay Guidance Manual (https://www.ncbi.nlm.nih.gov/books/ NBK53196/) eBook is a useful resource for scientists who are interested in drug discovery for rare diseases. It provides guidelines for assay development, high throughput screening, and structure activity relationship (SAR) analyses as well as many other areas related to drug development. With the development of molecular biology techniques, recombinant proteins, and engineered cell lines expressing a specific protein or a reporter system, in vitro assays have become popular tools for screening compounds. Two major classes of assays are considered for screening of compounds (Table 1 ). The first class is biochemical assays, which include measurements of enzyme activity, protein-protein interaction, and protein-DNA interaction. The proteins needed for these assays can be purified from primary tissues or expressed using recombinant systems. The other class of assays is cell-based assays using specially engineered cell lines. For example, reporter-gene assays use a signalgenerating reporter such as luciferase, beta-lactamase, and green fluorescent protein (GFP) that are typically linked to a special transcriptional promoter relevant to the disease target. Second messenger assays, such as those for G-protein coupled receptors, are designed to determine levels of cAMP and intracellular Ca 2+ release in special cell lines. These screening assays, usually first developed in 96-well plate format, need to be miniaturized and optimized to 384-or 1536-well plate formats for the next step in large-scale screening of compounds. Use of higher density assay plates reduces consumption of proteins, cells, and other reagents, FIGURE 2 The process of drug discovery and development for rare diseases: small molecules, biologics, and repurposing approaches.
and increases the throughput of these screens. Before it is adopted for large-scale screening of compounds, an assay should meet certain statistical criteria for robustness, including a signal-to-basal ratio greater than 2, a coefficient of variation less than 10% (less than 15% for a cell-based assay), and Z' factor greater than 0.5 (Inglese et al., 2007; Zhang, Chung, & Oldenburg, 1999) . Z' factor indicates the assay robustness for HTS, which is calculated from the sample means and sample standard deviations (Z' = 1-(3*SD (total signal) + 3*SD (basal signal) )/(Total signal-Basal signal)). Automated screening platforms usually consist of liquid handlers for dispensing proteins, cells, compounds, and other reagents; incubators providing control of gas composition, temperature, and humidity; plate readers for detection of assay results; a robotic arm system; and software integrating all these components together. The automated robotic system increases compound screening throughput and improves data quality by reducing human error due to repeated handling of hundreds and thousands of assay plates. The robotic screenings had been initially developed and used in drug companies and have recently been adapted by academic researchers in screening centers within universities and research institutes. Using the automated screening system, a throughput of 500,000 to 1 million wells per day can be achieved, with a primary screen thus completed very rapidly.
| Screening data analysis and hit selection
The screening data are loaded into a database and then analyzed using informatics software. The primary screening hits are typically selected using criteria such as "inhibition greater than 50%" for a single concentration screening, or "inhibitory concentration of 50% response (IC 50 ) less than 5 μM and efficacy greater than 70%" for quantitative high throughput screening (qHTS) (Inglese et al., 2006) . The primary hits consist of true positive compounds, as well as false positives such as autofluorescent and other types of non-specific compounds. These false positive and non-specific compounds have to be recognized and eliminated in the hit confirmation stage.
| Hit confirmation
The selected hit compounds are tested in secondary and tertiary assays to confirm their activity and selectivity. The same assay used in the primary screen is first used to confirm the activity of the compound in a concentration-dependent manner, typically using an independently sourced sample. A compound cytotoxicity assay using the same compound concentration and incubation time as the primary screening assay is usually employed to eliminate the toxic compounds. A counterscreen, such as a mock transfected cell line or a non-target protein, is used to eliminate the non-specific compounds including fluorescent compounds or compounds that otherwise interfere with the assay signal.
Additional experiments are then used to further confirm compound activities found in the primary screens. Tertiary assays with different formats (e.g., a luminescence assay versus a fluorescence assay), primary cells (instead of engineered cell lines), and cellbased assay (for compounds identified from biochemical assays) are usually employed at this stage. All these efforts lead to the identification and prioritization of relatively few lead compounds.
| Lead optimization
Once the lead compounds have been identified, chemistry optimization is an important next step for drug development, with the goal of improving the potency and selectivity of the small molecule. Medicinal chemists play a crucial role in the lead optimization process, not only by synthesizing newly designed compounds but also by leading the team effort in this important task, utilizing multiple types of experimental and computationally derived information. The lead compound undergoes several rounds of extensive medicinal chemistry modifications to improve its potency, selectivity, water solubility, ADME (absorption, distribution, metabolism, and excretion), and toxicity profile. Chemoinformatic analysis assists with defining the SAR of the lead compound.
In cases where structural information on the protein target is available, computational modeling of the interaction between a lead compound and its molecular target can yield new structures of chemical compounds with potentially improved binding properties. These rationally designed compounds are either synthesized by chemists or can be procured from millions of commercially available compounds.
The optimized lead compound then moves to preclinical drug development. 
| Preclinical drug development

| PHENOTYPIC SCREENING-BASED DRUG DISCOVERY FOR DISEASES WITH UNKNOWN TARGETS
For a genetic disease with known etiology and clear disease pathogenesis, molecular target-based drug discovery can be carried out as described above. However, the etiologies of many diseases are unknown, or in the cases of known genetic disorders, the cause-effect relationship between mutations and disease pathogenesis is unclear.
For example, only a small fraction of patients with amyotrophic lateral sclerosis (ALS) have a genetic basis for their illness, and the disease pathogenesis in most patients is unknown (Kiernan et al., 2011) ( Table 2) . In Huntington disease, the mutation in the HTT gene was identified in 1993, but the function of the mutated protein is not completely understood and the pathophysiology of the disease is unclear (Table 2) , thereby hindering the identification of a valid target for drug development. In such cases, a phenotypic screening approach is an alternative drug discovery strategy (Zheng, Thorne, & McKew, 2013) . This phenotypic screening approach for drug discovery, which is also called forward, or classical, pharmacology, allows for the activity of a drug to be determined without knowing its molecular mechanism and protein target (Takenaka, 2001) . In modern phenotypic screening, a characteristic change associated with the disease (i.e., phenotype) is used to develop a cell-based assay. For example, filipin staining was used to identify compounds that were effective for the treatment of Niemann-Pick disease type C (Vanier et al., 2016) and then subsequently identified as a broad spectrum histone deacetylase inhibitor (Marks & Breslow, 2007) . This drug is now under investigation for the treatment of glioblastoma multiforme and non-small-cell lung cancer (Friday et al., 2012; Reguart et al., 2014) . In 2014, Kevin Eggan, Clifford J. Woolf, and co-workers discovered a cellular phenotype of reduced delayed-rectifier gov identifier: NCT02450552).
The resource required for the development of new drugs for nearly 7,000 rare diseases is so huge that it will take well over a thousand years to develop effective therapeutics for all rare diseases using the classical drug development method. Addressing several rare diseases that share a common molecular etiology within a given project is especially attractive as the majority of rare diseases have an underlying genetic cause (Sun et al., 2016 
| Enzyme replacement therapy (ERT)
ERT is considered a cornerstone in rare disease treatment and has been reviewed previously (Ortolano, Vieitez, Navarro, & Spuch, 2014; Parenti, Andria, & Ballabio, 2015) . ERT has been approved for 8 lysosomal storage diseases: Gaucher disease type 1, Fabry disease, mucopolysaccharidosis types I, II, IVA, and VI, Pompe disease, and lysosomal acid lipase deficiency (Hoffman, Barr, Giovanni, & Murray, 1993; Ortolano et al., 2014; Sanford & Lo, 2014) . ERT has also been used for the treatment of one form of immunodeficiency, adenosine deaminase (ADA) deficiency (Aiuti et al., 2009 ) and for infantile or juvenile-onset hypophosphatasia (Whyte, 2017) . Development of enzyme replacement therapy starts with research on a small scale that produces recombinant proteins by yeast, bacteria, plant, and mammalian cells. Next, protein production is optimized and preclinical development of the lead protein product follows, including extensive profiling for immunogenicity. ERT usually requires intravenous administration at frequent intervals due to the relatively short halflife of enzymes in circulation, making it inconvenient for patients: for example, agalsidase beta (Fabrazyme®) has been approved for the treatment of Fabry disease since 2001 and has to be administered intravenously once every two weeks (Brady, 2006; Lidove et al., 2007) .
ERT has been efficacious at ameliorating the cardiac and renal complications in early-phase Fabry disease, lessening pain and improving the quality of life (Lidove et al., 2007) . However, the long-term use of ERT in advanced Fabry disease has not prevented progression toward organ failure and death (Weidemann et al., 2013 ).
In addition, some patients developed immune responses to the infused recombinant enzymes (Lidove et al., 2007) . The typically short half-life of enzymes and the need for repeated administration of large amounts of enzyme make ERT extremely expensive (an estimated US$200,000
per patient per year in 2012) (Rombach, Hollak, Linthorst, & Dijkgraaf, 2013) . Therefore, other treatments are still needed for better management of Fabry disease.
| Other recombinant human proteins
Hemophilia A is a genetic disorder in which blood does not clot normally due to deficiency of factor VIII. Several recombinant factor VIII products have been approved for the treatment of hemophilia A.
The main limitation with these recombinant proteins is their short halflives (8-12 hr for factor VIII), making repeated administrations necessary (Peyvandi, Garagiola, & Young, 2016) . A serious drawback of this and other replacement therapies is the development of antibodies directed against infused proteins, which reduces the efficacy of future treatment. One strategy for preventing antibody formation is to design genetically engineered proteins to better match the native proteins and to perform the intravenous infusion very slowly in order to minimize the immune reactions.
| Stem cell-based therapy
Stem cell-based therapy has been largely confined to cord blood or bone marrow transplants to differentiate hematopoietic stem cells into key subpopulations. Stem cell-based therapies are now under investigation for a diverse range of rare diseases, including degenerative neurologic disorders such as Krabbe disease (Hoffman & Escolar, 2006) , Fanconi anemia (Kelly et al., 2007) , and metabolic storage diseases such as the mucopolysaccharidoses (Sauer, Grewal, & Peters, 2004 
| Gene therapy
Gene therapy involves the delivery of a normally functioning gene as a nucleic acid polymer into the patient's cells to substitute for a mutant or missing gene in order to treat a specific disease. Thus, gene therapy is ideal for the treatment of genetic diseases, most readily those caused by loss-of function mutations in a single gene.
Currently, the lack of safe and effective methods to permanently deliver a gene to patients prevents the widespread application of gene therapy for the treatment of genetic diseases. Gene transfer efficacy is typically limited by insufficient delivery to the target tissue, negative immune response (autoantibody) to the treatment, and loss of therapeutic effect over time (Naldini, 2015; Sasano, Kikuchi, McDonald, Lai, & Donahue, 2007) . The adeno-associated virus (AAV) is the most commonly used vector for the delivery of genes in gene therapy . While AAVs are currently used as carriers in gene therapy, a more efficient and safer gene delivery vector remains to be discovered and developed.
To deliver nucleic acids into nuclei of cells, a number of barriers must be overcome. Extracellular barriers include inactivation by enzymatic degradation and recognition by the reticuloendothelial system (RES) (Hill, Chen, Chen, Pfeifer, & Jones, 2016) . After the genes penetrate the cell membrane, they encounter many intracellular barriers. Most exogenous genetic material is internalized through endocytosis pathways such as clathrin-mediated, caveolae-mediated, macropinocytosis, and phagocytosis. The associated vesicles are then trafficked from early endosomes to late endosomes to lysosomes where the nucleic acid cargo is degraded. The efficiency of the gene therapy platform is significantly reduced by vesicle trafficking. One of the strategies used to evade this endosomal entrapment is the design of carriers that release the nucleic acid cargo into the cytoplasm. Finally, the genes delivered to the cytoplasm need to traverse the nuclear membrane to enter the nucleus and integrate with a chromosome.
The nuclear transport is aided by nuclear pore complexes and is often a barrier for larger nucleic acids such as plasmid DNA. A nuclear localization signal peptide is used for active transport of DNA to the nucleus and as a method of restricting transgene expression to the desired tissues.
Generally, two types of carriers (vectors) are used in gene therapy (Kay, 2011) . Non-viral gene delivery carriers include lipoplex-mediated (liposome or phospholipids vesicle), polyplex-mediated (polymer), dendrimer-mediated (repetitively branched molecules), and graphene-mediated (a thin layer of pure carbon) gene delivery systems.
Because naked plasmid DNA does not offer good therapeutic efficacy due to premature degradation, poor cellular uptake, and low protein expression, special carriers are needed. The advantages of non-viral carriers include low immunogenicity, low cost, ability to deliver largesized DNA, lack of incorporation into host chromosomes, and lower mutation risk compared with viral carriers. Hydrophilic polymers like polyethylene glycol (PEG) have been conjugated to non-viral carriers to combat RES uptake and enhance the circulation time in blood.
However, the gene delivery efficiency of the non-viral delivery method needs to be further improved.
The second method employs viral gene delivery carriers.
Viruses offer a promising approach to deliver genes. The natural mechanisms of infection and transduction in viruses are very efficient, so two to three orders of magnitude less DNA is needed compared to non-viral carriers of similar efficacy (Ragusa, Garcia, & Penades, 2007) . Although it has been reported that some AAV serotypes (e.g., AAV9)
can cross the BBB to deliver genes to the CNS (Rastall & Amalfitano, 2015) , new methods are still needed to increase the delivery efficiency of genes to the brain and to simplify the overall gene delivery procedures.
The challenge of expressing sufficient amounts of functional proteins in target tissue still remains. For example, injection of the factor IX (FIX) gene, F9, into hemophilia B patients using a recombinant AAV2 vector resulted in the production of FIX in these patients, but the efficacy was hampered by transgene retention in the extracellular space of skeletal muscle, limiting plasma FIX expression to 1% (Manno et al., 2003) . Nathwani et al. (2014) reported the first unequivocal successful gene therapy for hemophilia B using an AAV8 vector by demonstrating stable and safe transgenic protein expression, resulting in plasma FIX expression of 1.4-7.2% after 3 years of follow-up.
There is a continual effort to improve the overall gene therapy platform. In particular, the use of gene editing technologies, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALEN), and most recently, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, is a rapidly evolving field (Gaj, Gersbach, & Barbas, 2013) . Tebas et al. (2014) 
| DISEASE MODELS
Disease models offer major opportunities for studying the phenotype of rare diseases, identification of drug targets, and evaluation of drug efficacy and toxicity. (Neuberger, Burton, Clark, & Van Goor, 2011) . Reprogrammed cells from normal and tumorous lung tissue in respiratory papillomatosis patients were used for cell viability tests to evaluate drug cytotoxicity (Yuan et al., 2012) . A clonal cell line derived from a pheochromocytoma of the rat adrenal medulla (PC12) expressing engineered huntingtin gene (HTT Q103-linked to GFP) was used for the detection of protein aggregates (GFP) to identify small molecule therapeutics (Titus, Southall, Marugan, Austin, & Zheng, 2012 (Ebert & Svendsen, 2010; Eglen & Reisine, 2011) . In 2012, familial dysautonomia iPSCs were screened against 6,912 small molecule compounds for candidate drugs. One small molecule was found to induce the transcription of the familial dysautonomia gene (IKBKAP) and rescue IKAP protein expression and the disease-specific loss of autonomic neuronal marker expression (Lee et al., 2012) . Another example, as discussed above, is the rapid advancement of retigabine into clinical trials upon discovery of its effect on the disease model using iPSCs from ALS patients. Fewer animals, fewer doses, and shorter exposures can be used to apply for an exploratory IND for rare diseases compared to common diseases (Vaquer et al., 2013) . In the preclinical phase, it is important to conduct proof of principle studies and establish solid pharmacokinetics/pharmacodynamics properties before thoroughly investigating a drug candidate in animal models of rare diseases. Recent technological advancements may assist in measuring drug target interactions. For example, the cellular thermal shift assay is capable of detecting drug target interactions in the context of cells lysates, live cells, and tissues (Jafari et al., 2014; Molina et al., 2013 ).
Compared to cell-based models, it is much more difficult to develop disease relevant animal models due to the long lead time and expertise needed to generate them (Vaquer et al., 2013) . Animals have many naturally occurring genetic diseases (e.g., hemophilia B in dogs) (Kay et al., 1994) , including rare cancers, so they can be used for evaluation of drug efficacy in vivo. For other disorders that do not occur naturally in animals, various techniques can be used to generate appropriate animal models (Vaquer et al., 2013) , such as in the case of Huntington disease (monkey) and cystic fibrosis (pig) (Wolfe, 2009 ). However, many rare genetic diseases still lack the desired animal models.
Both forward and reverse genetic manipulations are used to create mouse models. In forward genetics, specific genes are modified to reflect the pathophysiology of the disease. This is the fundamental approach to the study of the genetics and biochemistry of rare diseases, although it is expensive and time-consuming. Recent advancements in gene editing technology such as CRISPR/Cas9 may have the potential to significantly improve the process (Dow, 2015) . CRISPR/Cas9 was used to generate large animal models of neurodegenerative diseases to better mimic human disease progression (Tu, Yang, Yan, Guo, & Li, 2015) .
Reverse genetics is performed by treating animals with mutagenic agents and identifying genetic disorders by sequencing the genes of the animals. Deficiency of the Gmap-210 gene was identified in achondrogenesis mouse models using the reverse genetic approach (Smits et al., 2010) . The National Cancer Institute (http://mouse.ncifcrf.gov/) and the Jackson Laboratory (https://www.jax.org/jax-mice-and-services) offer a number of mouse models of genetic disorders.
| BIOMARKERS
A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Creatinine/cystatin C ratio for amyotrophic lateral sclerosis (ALS) [Bakkar, Boehringer, & Bowser, 2015; Tetsuka, Morita, Ikeguchi, & Nakano, 2013] Pharmacodynamic Detect the activity of a drug on the targeted pathway [Smith & Clatworthy, 2010] Prognostic Link with disease activity but may be distal from the targeted pathway Select patients with a more rapid rate of disease progression FDG-PET avidity for aggressive forms of disease in lung cancer, renal cell carcinoma and other cancers [Kelloff et al., 2005; Nakaigawa et al., 2016] a Many of the biomarkers may fit into multiple categories depending on the context in which they are used.
needed to validate biomarkers necessitates a consortium-type ap- well with renal function and could be measured as a biomarker to assess the efficacy of novel drugs (Whitfield et al., 2005) .
| SUMMARY
In summary, we have provided an overview of drug discovery and development strategies and methods, with an emphasis on rare genetic diseases. While small molecule drug discovery is still the main platform for rare genetic disease drug development, biologics such as recombinant proteins, antibody, stem cells, and gene therapy are expected to deliver major breakthrough therapies. The continued expansion of our knowledge of the biology and pathophysiology of rare diseases, combined with rapid advances in drug discovery technologies, will bring us closer to the discovery of much-needed new treatments.
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